Table 4.
Vaccines developed against SARS-CoV-2 strains. The details on type of vaccine, product, total amount of mRNA per dose, age, doses for normal and other people with health issues, including the details on booster doses as per National Institute of Health (NIH) and World Health Organisation (WHO) recommendations.
| S. No. | Type of vaccine | Product | Total amount of mRNA per dose | Age | For most people |
For moderately or severely immunocompromised people |
Booster doses | ||
|---|---|---|---|---|---|---|---|---|---|
| Doses/mL | Duration between doses | Doses/mL | Duration between doses | ||||||
| 1. | mRNA | Moderna (Monovalent) | 25 mcg per 0.25 mL | 6 months - 5 years | 2 doses of 0.25 mL | 4-8 weeks | 3/0.25 mL | 4 weeks | – |
| Moderna (Monovalent) | 50 mcg per 0.5 mL | 6-11 years | 2 doses of 0.5 mL | 4-8 weeks | 3/0.5 mL | 4 weeks | – | ||
| Moderna (Bivalent) | 25 mcg per 0.25 mL | 6-11 years | 3a | 8 weeks | 4 | 8 weeks | 0.25 mL | ||
| Moderna (Monovalent) | 100 mcg per 0.5 mL | 12-17 years | 2 doses of 0.5 mL | 4-8 weeks | 3/0.5 mL | 4 weeks | – | ||
| Moderna (Bivalent) | 50 mcg per 0.5 mL | 12-17 years | 3a | 8 weeks | 4 | 8 weeks | 0.5 mL | ||
| Pfizer-BioNTech (Monovalent) | 3 mcg per 0.2 mL | 6 months - 4 years | 3 doses of 0.2 mL | 3-8 weeks | 3/0.2 mL | 3-8 weeks | – | ||
| Pfizer-BioNTech (Monovalent) | 10 mcg per 0.2 mL | 5-11 years | 2 doses of 0.2 mL | 3-8 weeks | 3/0.2 mL | 3-4 weeks | – | ||
| Pfizer-BioNTech (Bivalent) | 10 mcg per 0.2 mL | 5-11 years | 3a | 8 weeks | 4 | 8 weeks | 0.2 mL | ||
| Pfizer-BioNTech (Monovalent) | 30 mcg per 0.3 mL | 12-17 years | 2 doses of 0.3 mL | 3-8 weeks | 3/0.3 mL | 3-4 weeks | – | ||
| Pfizer-BioNTech (Bivalent) | 30 mcg per 0.3 mL | 12-17 years | 3a | 8 weeks | 4 | 8 weeks | 0.3 mL | ||
| Moderna (Monovalent) | 100 mcg per 0.5 mL | 18 years and above | 2 doses of 0.5 mL | 4-8 weeks | 3/0.5 mL | 4 weeks | – | ||
| Moderna (Bivalent) | 50 mcg per 0.5 mL | 18 years and above | 3a | 8 weeks | 4 | 8 weeks | 0.5 mL | ||
| Pfizer-BioNTech (Monovalent) | 30 mcg per 0.3 mL | 18 years and above | 2 doses of 0.3 mL | 3-8 weeks | 3/0.3 mL | 3-4 weeks | – | ||
| Pfizer-BioNTech (Bivalent) | 30 mcg per 0.3 mL | 18 years and above | 3a | 8 weeks | 4 | 8 weeks | 0.3 mL | ||
| 2. | Protein subunit vaccine |
Novavax (Monovalent) | – | 12 years and above | 2a | 3-8 weeks | 2 | 3 weeks | – |
| Novavax (Monovalent) | – | 18 years and above | 2a | 3-8 weeks | 2 | 3 weeks | – | ||
| 3. | Adenovirus vector vaccine |
Janssen (Monovalent) | Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations | ||||||
a
Dosage mL not revealed.